Mebeverine Hydrochloride Strandhaven (Mebeverine Hydrochloride)

Mebeverine Hydrochloride is a gastrointestinal antispasmodic used to manage functional bowel disorders.

• Irritable Bowel Syndrome (IBS): reduces abdominal pain and spasm, improving stool regularity.
• Functional Bowel Disorders: alleviates chronic intestinal cramping and discomfort.
• Spastic Colon: relaxes colonic smooth muscle to ease bowel movement difficulties.

• Mebeverine Hydrochloride acts by directly relaxing gastrointestinal smooth muscle, likely through inhibition of calcium influx into muscle cells, which reduces contractility and spasm without significant anticholinergic activity. This localized action helps normalize bowel motility and lessen pain associated with functional gastrointestinal disorders.

Mebeverine Hydrochloride is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Nausea: mild to moderate upset stomach.
• Dry mouth: reduced salivation.
• Headache: transient cranial discomfort.
• Dizziness: occasional light‑headedness.
• Abdominal pain: mild cramping.
• Constipation: reduced bowel frequency.

Serious or Rare Side Effects

• Allergic reaction: rash, itching, swelling.
• Severe skin eruption: Stevens‑Johnson‑like rash.
• Angioedema: rapid swelling of face or throat.
• Cardiac arrhythmia: irregular heartbeat (very rare).
• Hepatic dysfunction: elevated liver enzymes.
• Anaphylaxis: life‑threatening systemic reaction.

Before initiating therapy, consider the following safety measures.

• Pregnancy: safety not established; avoid unless clearly needed.
• Breastfeeding: caution advised; limited data on excretion in milk.
• Renal impairment: use with clinical monitoring.
• Concomitant medications: review for potential additive antispasmodic effects.
• Medical history: disclose any gastrointestinal or cardiac disorders.
• Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Mebeverine may interact with several drug classes; monitor accordingly.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase mebeverine exposure.
• Other antispasmodics (e.g., hyoscine, dicyclomine): additive smooth‑muscle relaxation.
• Monoamine oxidase inhibitors (MAOIs): risk of severe hypotension.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy.
• Antihistamines: potential additive sedation.
• Tricyclic antidepressants: may enhance anticholinergic burden.